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the CC BY-NC-ND license (http://creaAbstract Ever since the ureteral stent design was fitted with a curl on both sides to prevent it
from migrating up or down the ureter some 40 years ago, its use has gained tremendous mo-
mentum, aiding in the rise and evolution of endourology and has confidently kept its place
in modern time urology. Over the past four decades, several designs, coating and biomaterials
have been developed, trying to reduce infection, encrustation and other stent related symp-
toms. As the ideal stent has not yet been discovered, different ways of helping patients with
their complaints have been researched. This review will cover these aspects of stent use in
urolithiasis.
ª 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The first description of using a ureteral catheter dates back
to over a century ago, when Shoemaker [1] described its
first appliance in women. Ever since, ureteral stents have
been used for a variety of urological conditions. Although
Zimskind et al. [2] described the first use of an indwelling
open-ended silicone stent in a ureter for malignant
obstruction in 1967, the design was still prone to migration.
To overcome this issue, Gibbons et al. [3] designed a new
stent with a distal flange to prevent proximal migration and
sharply pointed barbs to prevent distal migration, whichail.com (T.O. Tailly).
of Second Military Medical
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tivecommons.org/licenses/by-nc-became commercially available in 1974. Shortly thereafter,
Finney [4] and Hepperlen et al. [5], almost simultaneously,
reported on a new stent design to prevent both proximal
and distal migration with a J-shaped curl on each side of
the stent, the still known double pigtail or double-J stent.
Most new stent designs are alterations to this model and
will be discussed in more detail below.
2. Indications
Ureteral stents are implants used to provide drainage of the
upper urinary tract, when obstruction of the ureter is
present or anticipated. This obstruction may be due to in-
ternal or external issues, such as edema after manipulation
of the ureter, ureteral stricture, passage of stone fragments
or external compression of the ureter. Stents are also
frequently used in reconstructive surgery, where they serve
as a scaffold over which the ureteral reconstruction is toon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
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stents for urolithiasis.
The three main indications for placement of a ureteral
stent in urolithiasis are:
i. Drainage of obstructed ureter by stone fragment(s);
ii. Following ureterorenoscopy;
iii. Prophylactic insertion before extracorporeal shock
wave lithotripsy (ESWL) or (flexible) ureterorenoscopy.2.1. Acute drainage of obstructing urolithiasis
Drainage of the upper urinary tract is not mandatory for
each obstructing stone. It is however absolutely indicated
in cases of bilateral obstruction, obstruction of a solitary
kidney, uncontrollable pain or when the obstruction is
associated with a urinary tract infection (UTI) or sepsis.
Depending on multiple variables, including center and
surgeon preference, either a stent or nephrostomy may be
preferred to acquire drainage. In the most recent European
Association of Urology (EAU) guidelines, ureteral stents and
percutaneous nephrostomy tubes are considered equally
effective (level of evidence 1b) for decompression of the
renal collecting system [6]. To date, only two randomized
controlled trials (RCTs) have directly compared effective-
ness of retrograde ureteral catheterization and percuta-
neous nephrostomy in adult cases of infected
hydronephrosis associated with ureteral calculi. They found
no statistically significant difference in drainage efficiency
or recovery time from sepsis [7,8]. In a large retrospective
study by Sammon et al. [9], using the Nationwide Inpatient
Sample of the United States between 1999 and 2009, the
authors demonstrated that a stent was placed for renal
decompression in 87.7% of patients. Patients undergoing
percutaneous nephrostomy placement were more likely to
have comorbidities, and had a higher rate of sepsis and in-
hospital mortality. This probably reflects the fact that
sicker patients were more likely to receive a nephrostomy
tube rather than demonstrating causality of outcome with a
nephrostomy tube [9]. This was corroborated by a smaller
retrospective study, indicating indeed that patients
receiving a nephrostomy tube were more acutely ill and had
larger stones than patients receiving a stent [10].
In the pediatric population, Elsheemy and asso-
ciates [11] compared acute drainage of bilateral obstruct-
ing ureteral calculi with unilateral nephrostomy to bilateral
ureteral stenting. As percutaneous nephrostomy tube
insertion was associated with more, albeit low grade,
complications and as double-J stent placement facilitated
subsequent endourological procedures, the authors would
advocate stent placement rather than nephrostomy tube
insertion in this setting. For stones >2 cm, a percutaneous
nephrostomy tube would be preferred as attempts at stent
placement resulted more frequently in mucosal complica-
tions in this subgroup.
2.2. Insertion of stent after ureterorenoscopy
Both the EAU and American Urological Association (AUA)
guidelines state that stent placement after uncomplicatedureteroscopy can be omitted in select cases [6,12]. In case
of a solitary kidney, anatomic abnormalities, ureteral
perforation, residual fragments or other risk of complica-
tion, ureteral stents are still suggested.
These recommendations are based on the initial report
of safely omitting a stent after uncomplicated ureteroscopy
by Denstedt et al. [13] and many others that followed af-
terwards corroborating these results [14]. The most recent
meta-analysis by Wang et al. [14] identified 22 RCTs,
involving stenting after ureteroscopy or after ESWL
including a total of 2552 patients. The authors demon-
strated pain, dysuria, hematuria and irritative urinary
symptoms to be significantly more common in the stented
group (OR and [95%CI] were respectively 2.69 [1.43, 5.06],
3.97 [2.24, 7.01], 3.09 [1.45, 6.60] and 4.40 [2.12, 9.10]).
Operating time was on average 5 min longer in the stented
group and no significant differences were seen in stone free
rate, length of hospital stay and infection rate. The risk of
unplanned readmissions was significantly higher in the
unstented group (ORZ0.54, 95%CI [0.34, 0.87], p < 0.01).
Despite compelling evidence in favour of not stenting a
patient after an uncomplicated ureteroscopy, it is still
common practice to routinely do so. This is reflected in an
analysis of the Clinical Research Office of the Endouro-
logical Society (CROES) Ureteroscopy Global Study, a large
prospective, observational study conducted in 114 urol-
ogy departments across 32 countries including 11 885
patients [15]. The authors identified that a stent was
placed in 63.2% after ureteral stone treatment and in 79.5%
after renal stone treatment. Interestingly, there were great
geographical differences in routine stent placement prac-
tice ranging from 28.9% in Iran to 96.1% in Japan [15].
Whether or not to place a stent after the use of a ure-
teral access sheath (UAS) is still a topic of debate. Although
expert opinion would indicate that it is recommended,
retrospective data nuances that it would be safe to omit a
stent in pre-stented patients treated with ureteroscopy with
a UAS [16e18]. To date, only one RCT has been published
demonstrating that it is safe and feasible to omit stent
placement after the use of a UAS during ureteroscopy [19].
In a climate of increasing society healthcare costs, the
question of cost when placing or omitting a stent after
uncomplicated ureteroscopy is gaining importance. An
Austrian study by Seklehner et al. [20] in 2017 simulated the
total cost for both scenarios including costs of stent
placement, stent removal and postoperative complication
management after uncomplicated semirigid ureteroscopy
as well as costs of unplanned hospital visits and read-
missions. Based on a decision tree model extracted from 12
RCTs, they calculated a total cost increment of V138.25 in
public insured and V599.82 in privately insured patients for
placing a stent. Although these data were based on the
Austrian health care system and cannot necessarily be
extrapolated to other national healthcare systems, they
unveiled a previously unreported issue in the debate. The
discrepancy may become even more apparent when
including cost to society by work incapacity [21].
Additional to the debate of whether or not to place a
stent, the ideal indwelling time after ureteroscopy is also
controversial. The heterogeneity in dwell-time in the RCTs,
ranging from 3 to 28 days, demonstrates the lack of
consensus [14]. The only two studies on the subject are
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days has an increased risk of adverse events and fever and
that a ureteroscopy performed in patients that had a stent
indwelling for >30 days have a higher risk of post-
ureteroscopic sepsis [22,23]. To date, there is no prospec-
tive randomized data to determine the most ideal stent
indwelling time.
Ultimately, it is up to the treating physician to decide
whether or not a procedure was uncomplicated and to es-
timate the risk of post-operative complications, weighing
the absence of stent-related symptoms against the risk of a
higher readmission rate when omitting stent placement.
2.3. Pre-stenting in ESWL or (flexible)
ureterorenoscopy
Prophylactic stenting prior to ESWL has been a common
practice in the past to avoid ureteral obstruction by pas-
sage of stone fragments or steinstrasse formation after
lithotripsy.
A meta-analysis of eight RCTs, including 876 patients,
failed to demonstrate a significant difference in stone-free
rate, auxiliary treatment rate, UTI, hematuria or pain [24].
The overall results would indicate that stents do prevent
steinstrasse, however this result was heavily skewed by the
data of Al-Awadi et al. [25], that treated stones of
15e35 mm. In subgroup analyses, there was no significant
difference between stented or non-stented patients. The
incidence of lower urinary tract symptoms was significantly
higher in the stented group, compared with the stentless
group (RRZ4.10, 95%CI [2.21, 7.61], p < 0.000 01) [24].
Based on these results, stent placement in prevention of
steinstrasse when treating very large stones (>15e20 mm)
with ESWL can be beneficial.
The jury is still out on whether or not pre-stenting prior
to ureteroscopic treatment of urinary stone disease should
be routine practice. So far, no prospective randomized data
are available demonstrating a significant benefit. The pri-
mary failure rate of ureteroscopy, i.e. the incapacity of
reaching the calculus to be treated with the ureteroscope,
is generally less than 10% and is more common in younger
females [26]. Passive dilation by ureteral stenting has been
reported to occur after 2 weeks [27].
Retrospective data suggest that stone-free rates of
ureteroscopy are higher in pre-stented patients. A sub-
analysis of the CROES Ureteroscopy Global Study identified
11.9% of patients with ureteric calculi and 36.4% of patients
with renal calculi to have been pre-stented [28]. In-
dications for stent placement were not recorded, but pre-
stented patients had more comorbidities and were more
likely to have smaller stones. The analysis demonstrated a
higher stone free rate for pre-stented renal stones, but no
benefit for ureteric stones [28]. These results were
confirmed in a recent meta-analysis of nine retrospective
studies, including 11 239 patients, identifying a stone-free
rate in favour of pre-stented patients (OR [95%CI]: 1.6
[1.19, 2.15]) [29].
Based on these retrospective studies, the EAU guidelines
state that it is not necessary to routinely pre-stent all pa-
tients before ureteroscopy, but that it may improve the
stone-free rate and reduce complications [6].Additionally, placement of a UAS has been shown to be
easier in pre-stented patients [30].
Considering the low level of evidence, heterogeneity of
data and contradicting results, together with the fact that
stents cause considerable stent-related symptoms in a large
part of patients, it may be prudent to reserve pre-stenting
for patients in whom primary ureteroscopy has failed or in
whom stent placement rather than primary ureteroscopy
was indicated at presentation. A second ureteroscopy can
be attempted within 2e4 weeks.
3. Stent-related complications
Despite the obvious benefits of ureteral stents, they may also
induce adverse events. Ureteral stents are notoriously
fraught with relevant patient discomfort, negatively
affecting quality of life. The presence of an indwelling
foreign body can also lead to biofilm-formation, which may
promote development of UTIs or formation of encrustations,
complicating subsequent stent removal.
3.1. Stent-related symptoms (SRS) and quality of
life
Joshi et al. [31] identified 80% of patients with indwelling
ureteral stents to have at least one urinary symptom. These
SRS range from bladder/flank pain to storage symptoms to
hematuria. Although the underlying pathophysiology behind
these complaints are not yet fully elucidated, bladder wall
and trigonal irritation by the distal coil as well as ves-
icoureteral reflux and retrograde pressure transmission have
been proposed as underlying mechanisms [32,33]. Apart
from being bothersome for the patient, stent-related
symptoms can also lead to socio-economic burden. Leibo-
vici et al. [34] identified that among working patients, 45%
lost at least 2 labor days during the first 14 days after stent
insertion and 32% were still absent from work by Day 30. For
Swiss patients the median cost associated with stent
placement, removal, work incapacity and treatment of SRS
was calculated by Staubli et al. [21] to be USD455 (113e11
948) per patient for the entire indwelling time and USD15
(4e398) per patient per day. Work incapacity was the
biggest cost (78.1%), with younger patients showing a higher
tendency to miss at least 1 working day.
Not all patients are equally bothered by stents and
patient-reported outcome measures can help in quanti-
fying patient discomfort. The absence of a comprehen-
sive follow-up tool stimulated Joshi et al. [35] to develop
a disease-specific questionnaire, the Ureteral Stent
Symptom Questionnaire (USSQ), consisting of six sections:
Urinary symptoms, body pain, general health, work per-
formance, sexual matters and additional problems. This
validated questionnaire has proven to be extremely useful
in comparing treatments and stent designs in research for
SRS and has been translated and validated in several lan-
guages [36e42].
3.2. Biofilms, UTIs and encrustations
Biofilm formation on the stent surface has been implicated
as an important step in the process of stent associated UTI,
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process, resulting in a complex, multilayered organized
structure composed of organic molecules, fluid-filled
spaces and bacteria that adhere to the stent surface [43].
Within this biofilm, microorganisms are protected from host
defenses and antibiotics, which may lead to an accelerated
development of antibiotic resistance. The deposition of
conditioning film molecules, the first step of biofilm for-
mation, starts almost immediately after stent insertion in
the human body [44]. Bacterial colonization was reported
in 24% before 4 weeks, 33% after 4e6 weeks and 71%
thereafter [43]. Additionally, diabetes mellitus, chronic
renal failure and pregnancy were associated with a higher
risk of stent related bacteriuria [45]. Routine screening for
and treatment of asymptomatic bacteriuria however is not
recommended. A continuous low-dose antibiotic treatment
during the entire stent-indwelling time showed no reduc-
tion in quantity and severity of UTIs and has no effect on
SRS, compared to a single peri-interventional antibiotic
prophylaxis at stent placement [46].
Urease producing bacteria in the biofilm and lithogenic
characteristics of urine in stone formers seem to be the
most likely culprits influencing encrustation of the stent
surface [47,48] (Fig. 1). The indwelling time is the most
important risk factor for encrustation with encrustations
presenting on stents in 9.2%e26.8% before 6 weeks,
47.5%e56.9% after 6 to 12 weeks and 75.9%e76.3% there-
after [49,50]. These encrustations may block urinary
drainage, resulting in patient symptoms or significantly
complicate stent removal [51].
Although several modifications of the stent surface to
reduce biofilm formation and bacterial colonization have
been investigated, at this moment no available materials or
coatings have been proven to prevent or reduce biofilm
formation to a clinically relevant extent [43].
3.3. The “forgotten stent”
Every stent that has been placed, will eventually need to be
removed or replaced. Despite best efforts however,Figure 1 Encrustations on stent surface after 2 weeks
indwelling time in chronically infected urinary tract system.forgotten stents still emerge, often leading to major com-
plications like encrustation, fragmentation, obstruction of
urinary flow, renal failure, and even death [52]. In a series
of 22 forgotten stents, Monga et al. [51] found that after a
mean indwelling time of 22.7 months, 68% of stents were
calcified, 45% were fragmented and 14% were both calcified
and fragmented (Fig. 2). Due to these issues, removal of the
device may be a challenging endeavor, often requiring
multiple procedures combining different endourological or
even open or laparoscopic approaches [51,53]. As such, the
removal of a forgotten stent can be up to 7-fold more
expensive than the timely removal of a stent [54]. To avoid
both legal and surgical consequences of forgotten stents,
several approaches have been developed to monitor
indwelling ureteral stents. Almost all of these are based on
computer programs in which stent placement is registered
and an automatic reminder is sent to patient and/or urol-
ogist after a preset period of time [55e57]. As this still
requires proper registration of every stent insertion, human
error cannot be eliminated completely.
3.4. Treatment and prevention of stent
complications
Since Finney [4] described the first double-J stent in 1978,
there has been a continuous search for the “perfect”
or “ideal” stent. This stent should provide excellent
drainage, resist migration, encrustation and infection,
provoke no reaction or symptoms in the patient, be inex-
pensive and be easy to insert and remove. The main ap-
proaches for prevention and treatment of SRS and
complications are stent design and drug therapy. Other
focuses are stent positioning, patient education and
intravesical drug application [58].
4. Developments in improving stent
characteristics
4.1. Stent composition
4.1.1. Biomaterials and biocompatibility
A biomaterial is defined as a natural or synthetic substance
that interfaces with tissue [59]. With increasing biocom-
patibility, there is a decreased reaction of the human body
on the stent biomaterial. Currently used biomaterials for
stent construction are synthetic polymers or (proprietary)
copolymers such as silicone, polyethylene, polyurethane,
C-Flex (Cook Medical, IN, USA), Silitek (Surgitek, WI,
USA), Pellethane (Bard Medical, GA, USA), Vertex
(Applied Medical, CA, USA) and Percuflex (Boston Scien-
tific, MA, USA).
Although silicone is still the most biocompatible material
currently available, its softness and high friction coefficient
can make stent insertion in a tortuous or obstructed ureter
very difficult [59,60]. The stiffer and easier to insert poly-
ethylene is no longer used for stent manufacturing due to
biocompatibility issues and fragmentation of stents over
time [60]. Polyurethane is an inexpensive polymer
combining the flexibility of silicone with the stiffness of
polyethylene. Unfortunately, polyurethane stents appear
Figure 2 Not all forgotten stents encrust over time. (A) Forgotten stent after 1 year in a cystinuric patient. (B) Forgotten stent
after 2 years in a paraplegic patient.
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ulceration and erosion than other stents in an animal
study [59,61]. Multiple proprietary (co)polymer biomate-
rials have been developed in search of an ideal combination
of stiffness to increase ease of handling, flexibility to
decrease stent related symptoms and biocompatibility to
prevent encrustations and infections. Based on in vitro
testing, Mardis and colleagues [59] suggested C-flex and
Percuflex to be the most suitable biomaterials. Results
from an animal study demonstrated silicone and C-flex to
cause fewer tissue reactions in dog ureters [61]. Addition-
ally, silicone stents were more resistant to encrustations
compared to polyurethane of Percuflex stents in an
in vitro model [62].
4.1.2. Hardness/durometer
Durometer is a measure of the resistance of the material to
a calibrated pin gauge under standard test conditions, with
a higher durometer indicating increased hardness. Varia-
tions are seen as a result of strength of cross-links in bio-
materials used, with more cross links resulting in higher
durometer [63]. A “softer” biomaterial would intuitively
cause less urinary symptoms than a “firmer” ureteral stent.
Lennon et al. [64] performed an RCT involving 155 patients
comparing polyurethane to Sof-Flex stents (Cook Medical,
IN, US). Besides a significantly higher incidence of dysuria,
renal and suprapubic pain in the firm stent group, no other
differences in tolerance, encrustation or stent positioning
could be identified. Normal activity and return to work was
higher in patients with softer stents (67% vs. 45%). A similar
RCT by Joshi et al. [63] with placement of a firm
(Percuflex 6 Fr, Boston Scientific, MA, USA) versus soft
(Contour 6 Fr, Boston Scientific, MA, USA) stent in 130
patients demonstrated no significant differences in USSQ-
score between the two groups at 1 or 4 weeks after stent
insertion.
Dual-durometer stents, such as the Sof-Curl (ACMI, MA,
USA) and the Polaris (Microvasive/Boston Scientific, MA,
USA), incorporate a smooth transition from a firm bioma-
terial at the proximal end to a softer biomaterial at the
distal end, to minimize bladder discomfort. Two small RCTs
however failed to demonstrate a significant benefit of the
Polaris stent compared to the Percuflex (Boston Scien-
tific, MA, USA) or InLay (Bard Medical, GA, USA) stent
[65,66]. Park et al. [65] were able to identify someadvantages in terms of pain, physical activities, work, and
antibiotics use in favor of a softer stent tail.
4.2. Stent design
4.2.1. Stent diameter and drainage capacities
The total urinary flow in a stented ureter consists of
intraluminal and extraluminal flow. Brewer and col-
leagues [67] demonstrated in an in vivo porcine model that
with increasing stent diameter, as expected, the intra-
luminal flow increases. Efforts have been made to increase
extraluminal flow with several stent designs such as the
Towers stent (Cook Medical, IN, USA) and the LithoStent
(ACMI, MA, USA), which have grooves spiraling down the
exterior of the stent, or the Spirastent (Urosurge Inc,
Coralville, Iowa), which is spiral shaped [68]. The Towers
stent however was demonstrated to provide a lower total
flow than other stents in an experimental setup [69].
Experimental results for the Spirastent were not consis-
tent and a human trial failed to demonstrate its supposed
benefits [69e71].
Side drainage holes may promote drainage, but can also
make the stent more prone to breakage or buckling during
insertion [72]. The importance of side holes in promoting
urine flow seems to increase with narrowing of the ureteral
lumen [73].
Interestingly, two RCTs demonstrated that larger diam-
eter stents do not cause more SRS. The authors found no
significant differences in terms of pain or irritative symp-
toms. There was however a tendency to higher migration in
the 4.7 Fr stent group [74,75]. This could persuade the
physician to place a larger stent instead of a small caliber
stent. On the other hand, a smaller stent would intuitively
allow larger stone fragments to pass alongside the stent.
The MicroStent (Percutaneous Systems, CA, USA) is a 3 Fr
stent that utilizes a film anchor that is deployed above the
ureteral obstruction as proximal retaining mechanism. In an
experimental study by Lange et al. [76] the MicroStent
showed a drainage capacity equivalent to a 4.7 Fr stent and
better than a 3 Fr double-J stent. No results of human trials
with this novel stent have been published to date.
4.2.2. Stent length
Most contemporary ureteral stents are manufactured in a
variety of sizes. As several groups have reported that a stent
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stent symptoms, placing a properly sized stent is of impor-
tance [77e79]. Additionally, a stent that is too short can
result in stent migration, with the need for additional ma-
nipulations [80]. Although efforts have been made to iden-
tify a reliable predictor of the proper stent length for each
patient, the gold standard for measuring the required stent
length remains insertion of a graduated ureteral catheter,
measuring the distance between ureteropelvic junction
(UPJ) and ureterovesical junction (UVJ) [81]. Interestingly,
post-mortem measurements of ureteric length could not
identify a significant correlation with any anthropomorphic
measurement [82]. Measurements deducted from pre-
operative CT imaging or acquired during the procedure by
fluoroscopic measurement appear to provide an adequate
estimate of the appropriate stent length [81,83,84]. Ideal
stent length for children has been formulated by Palmer JS
and Palmer LS [85] as “child’s age þ10 cm”.
In an effort to provide a “one-size-fits-all” solution,
reducing stock with stents of different lengths and obvi-
ating the process of estimating the appropriate stent
length, variable length stents were designed. Although this
results in more stent material in the bladder, this material
is coiled up, preventing it from crossing the midline of the
bladder. Calvert et al. [86] compared the standard Con-
tour 6 Fr, 24 cm stent (Boston Scientific, MA, USA)) with a
Contour multi-length stent, Contour VL 6 Fr, 22e30 cm
(Boston Scientific, MA, USA) and found no difference in
USSQ score on all domains.
In an observational study, El-Nahas and associates [79]
identified calyceal positioning of the upper coil as an in-
dependent predictor of SRS. In contrast, Liatsikos et al. [87]
demonstrated in a small RCT that upper pole positioning of
the proximal coil was associated with fewer SRS. This can
probably be attributed to a shorter intravesical stent
portion when the stent is positioned higher in the kidney.
4.2.3. Distal stent coil adjustments
As the distal coil of the stent is hypothesized to be in part
responsible for SRS, several design alterations have been
proposed to reduce SRS. The conventional distal coil has
been replaced by a loop, a tail and a simple suture in
several trials [88e90].
Lingeman et al. [88] assessed two new stent designs, in
which the distal pigtail end was replaced by a short or long
3 Fr loop. These stents were prospectively evaluated with
the USSQ in 236 patients next to two standard stents
(Polaris and Percuflex Plus; Boston Scientific, MA, USA).
Although the authors suggested an improved stent comfort,
they could not demonstrate a significant benefit of the Loop
stents over the conventional stents. The Tail stent (Boston
Scientific, MA, USA) consists of a 7 Fr proximal pigtail and a
7 Fr shaft which tapers to a lumenless straight 3 Fr tail
to decrease stent-related bladder irritability. In a small
RCT, a significant 21% decrease in overall lower tract
symptoms was identified in comparison to standard stents
(Percuflex) [79]. Olweny et al. [70] demonstrated the
stent to provide similar drainage in comparison to conven-
tional stent designs. Despite these advantages, the stent is
unfortunately no longer available.
To mimic this design, Vogt et al. [90] designed a self-
adjusted ureteral stent by removing the distal coil of astandard polyurethane stent and attaching a 0.3 Fr suture
for subsequent removal of the stent. In their prospective
study with 79 patients, they identified a significant decline
in SRS in 24 patients after a classic stent was replaced by a
suture stent. Interestingly, the suture appeared to provide
adequate ureteral dilation, allowing subsequent uretero-
scopy. The authors observed migration of the suture into
the urethra in 13 patients, without causing incontinence
and proximal migration in three patients.
Chew and associates [91] recently reported on a new
design concept for ureteral stents. They evaluated pain
scores in 15 patients that had a Percuflex Helical stent
inserted and compared them with a historical patient
group, stented with a standard Percuflex stent (Boston
Scientific, MA, USA). The Helical stent is a standard
Percuflex stent, cut in a spiral fashion in order to provide
more flexibility and the ability to conform to the natural
anatomy of the ureter. The Helical stent-group required
significantly less analgesics and had equivalent pain scores.
SRS by means of USSQ was unfortunately not inquired.
4.2.4. Anti-reflux mechanism
Another factor implicated with SRS is vesicoureteral reflux
(VUR), induced by the stent bypassing the antireflux valve.
Yossepowitch and colleagues [92] reported 27% of stented
patients to have VUR immediately after insertion, which
increased to 76% after an average of 9 weeks. Similarly,
Sameh and Eid [33] demonstrated 80% of patients to have
pressure transmission from the bladder to the kidney
with pressure flow studies in 20 patients that had both a
double-J stent and nephrostomy tube. To prevent this
phenomenon from occurring, several stents with an anti-
reflux mechanism have been designed. At the distal end of
the stent, they consist of a valve mechanism that allows
drainage of the kidney but closes with increasing intra-
vesical pressure [94e96].
Ritter et al. [93] included 29 patients in an RCT
comparing an antirefluxive stent to a regular stent.
Although the antirefluxive stent appears to cause less SRS,
the results were not statistically significant, probably due
to a small sample size. In a larger RCT, including 133 pa-
tients, Ecke et al. [94] reached a significantly lower
complication rate and higher acceptance rate with an
antirefluxive stent. Kim and colleagues [95] developed a
flexible polymeric flap valve that can be attached to the
intravesical portion of a ureteral stent for the prevention of
VUR. This flap valve closes off when intravesical pressure
rises above 20 cmH2O. In an in vivo porcine model, a
significantly lower VUR grade was noted without occurrence
of antegrade urinary obstruction.
Although many promising design alterations have been
developed, these have not penetrated in routine clinical
practice yet. Larger, multi-center, well-designed studies
will be needed to confirm these preliminary findings and
persuade widespread adoption of stents that cause fewer
symptoms.
4.2.5. Coatings
To increase biocompatibility in order to reduce device
associated UTI or encrustations or to decrease the surface
friction coefficient to facilitate stent manipulation, several
different coatings have been applied on stent surfaces.
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4.2.5.1. Surface friction. A hydrogel is a polymeric
biomaterial that results in a hydrophilic layer when hy-
drated, thus decreasing the surface friction coefficient and
facilitating stent insertion [59]. In vitro results have not
been able to consistently support the theoretical
advantage against bacterial colonization and encrustation
[96e98]. Hydrogel-coated stents impregnated with
antibiotics however did show an antibacterial effect in an
in vitro environment [97].
4.2.5.2. Resistance to bacterial colonization and
encrustation. In an in vivo human trial, phosphorylcholine-
coated ureteral stents showed less encrustation and
colonization by bacterial biofilm than conventional stents in
the same patients after a 12-week period [99]. Poly(vinyl
pyrollidone)-coated biomaterials were demonstrated in an
in vitro study to be very hydrophilic and more resistant to
encrustation and bacterial adherence than uncoated
polyurethane or silicone [100].
Heparin, a strong negatively charged glycosaminoglycan,
has been demonstrated to resist encrustations in compari-
son to uncoated polyurethane stents after 1 month
indwelling time in a human trial [101]. The authors also
reported on two patients in whom stents had remained free
of encrustations after 10 and 12 months [101]. Interestingly
the heparin coating was not successful in preventing bac-
terial adhesion in an in vitro study [102].
In an observational study with 10 patients that were
previously known with encrusting stents, diamond like
carbon, a chemically inert substance, coated onto ureteral
stents appeared to decrease encrustations and friction
during insertion [103].
4.2.5.3. Drug-eluting stents. After promising animal tests
with the Triumph stent (Boston Scientific, MA, USA), a
triclosan-eluting stent, two human trials were performed
[104e106]. In short-term stented patients, the Triumph
stent demonstrated a significant reduction in SRS without
reducing biofilm formation or encrustation [107]. In
chronically stented patients, fewer symptomatic UTI were
identified with a reduction in antibiotics use, while no
fewer positive urine cultures were recorded [105]. It should
be noted however that in both studies, patients receiving a
control stent were given a course of post-operative
antibiotics while they did not receive any antibiotics when
the Triumph stent was placed.
A ketoroloac-eluting stent, the Lexington stent (Boston
Scientific, MA, USA), was designed with the goal of reducing
stent-related pain. In a large multi-center RCT, Krambeck
et al. [107] could not demonstrate a significant benefit over
conventional stents in the entire population. Only in a
subgroup of young men, there was a statistically lower need
for pain medication.
Based on experience with intravesical instillations with
ketorolac for stent symptoms [108], a ketorolac-eluting
stent was designed (Lexington stent, Boston Scientific,
MA, USA). In a multicenter, randomized prospective studywith 276 patients this stent appeared safe, but showed no
clear advantage in prevention of SRS. Only in a subgroup of
young men, there was a statistically lower need for pain
medication [107].
In an RCT with 126 patients, El-Nahas et al. [109] could
not identify a clinically significant benefit of silver sulfa-
diazine coated stents over non-coated stents.
Although a large variety of other coatings has been and is
being tested in vitro demonstrating promising results,
human trials are still lacking to support their commercial
use [110].5. Medication
5.1. Alpha 1-blockers
Alpha1-blockers are often prescribed for outflow obstruc-
tion due to prostatic hyperplasia, but based on its working
mechanism and the location of alpha1-adrenoreceptors in
the ureter and bladder trigone, they can also affect SRS
[111,112]. The first placebo-controlled RCT, published in
2006, demonstrated alfuzosin to confer a significant benefit
to stented patients with a relief in SRS [113]. The most
recent meta-analysis on the effect of alpha 1-blockers on
SRS by He et al. [114], included 16 studies with a total of
1 489 patients. Despite considerable heterogeneity in data,
alpha-blockers appear to provide a significant relief in SRS
on all USSQ subdomains except on work and additional is-
sues [114]. Although alfuzosin and tamsulosin are the most
investigated drugs to this purpose, a recent RCT including
239 patients also demonstrated a significant benefit of
doxazosin for SRS [115].
5.2. Antimuscarinics
As SRS may resemble complaints of an overactive bladder
(i.e. frequency, urgency, urge-incontinence), the use of
antimuscarinics has been advocated and studied. Wang
et al. [116] performed a meta-analysis of the available RCTs
evaluating solifenacin or its combination with tamsulosin
for the treatment of SRS, including ten studies comprising
1786 patients. Solifenacin monotherapy provided a signifi-
cant reduction in total USSQ and hematuria-score and was
not superior to tamsulosin. Although no published literature
is available on the use of mirabegron, a beta-agonist,
several trials are ongoing for its use in treating SRS (clin-
icaltrials.gov: NCT02095665, NCT02462837, NCT02744430).
5.3. Combination products
Whereas Wang and associates [116] concluded that the
combination of solifenacin and tamsulosin provides no sig-
nificant benefit over solifenacin monotherapy, Zhang et al.
[117], in a meta-analysis also including RCTs on other
antimuscarinics in combination with alpha-blockers, re-
ported a significant improvement in International Prostate
Symptom Score and quality of life with combination ther-
apy in comparison to either monotherapy. With only three
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analysis of these studies then again could not identify a
benefit of combination therapy.
5.4. Analgesics
Since pain in the bladder, lumbar, flank, groin and geni-
tal region is frequently stent-related complaints, analgesic
substances (paracetamol, non-steroidal anti-inflammatory
drugs, opioids) are regularly prescribed. There are howev-
er, surprisingly, no trials assessing the influence of classical
analgesics on SRS [58].
5.5. Intravesical treatment
To minimize side effects of oral medication, medical
treatment can also be instilled in the bladder. In a double-
blind RCT an intravesical instillation with oxybutynin,
alkalinized lidocaine, ketorolac or a control solution was
given immediately after stent placement at time of shock
wave lithotripsy. The authors found a significant decrease
in stent-related discomfort 1 h after instillation with
intravesical ketorolac and oxybutynin in comparison to the
control group [108]. These effects were however only short-
lived (maximum 2 h), which renders it impractical in clin-
ical settings.
Two small studies investigated the effect of injections in
the bladder wall. Sur et al. [118] gave five injections of
2 mL 0.5% ropivacaine around the ureteral orifice and
compared this with placebo injections. A slightly decreased
pain and symptom score 8 h postoperatively until stent
removal could be noted, but none of these differences was
statistically significant. In an RCT, Gupta et al. [119]
injected botulinum toxin in the detrusor muscle in three
locations around the ureteral orifice of 30 patients and
showed a significant decrease in pain score, but no
improvement in USSQ scores. Due to lack of data, no clear
conclusions can be made.
6. Patient education
When planning to stent a patient, the patient should be
informed of the possible side-effects of this treatment as
part of the informed consent. Abt and colleagues [120]
aimed to quantify the influence of patient education on
the patient’s experience. The authors identified a small,
but significant correlation (Pearson r Z 0.40, 95%CI
[0.58, 0.19], p Z 0.02) between USSQ-scores and high-
quality patient education, without however demonstrating
a reduction in incidence of symptoms. These results how-
ever do warrant further research on the influence of pa-
tient education on stent related symptoms and
complications.
7. Procedures for stent removal
An indwelling stent after stone treatment has to be removed
at some point in time, which is generally performed byflexible cystoscopy in an outpatient setting. To avoid
possible complications associated with this procedure,
several new methods of stent removal have been designed.
7.1. Mechanical (self-)removal with suture
Multiple reports discuss the use of tethered stents that have
a string attached to the distal end of the stent. This string is
left outside of the urethra, so the stent can be removed by
the patient, physician or nurse and obviates cystoscopy.
Apart from avoiding the possible complications related to
a cystoscopy, this method can also reduce healthcare-
related costs produced by a cystoscopy. An Australian group
reported a cost-saving of A$864.5 per case when using teth-
ered stents [121]. There are however concerns of poten-
tial dislodgement, discomfort due to the string and risk
of developing a UTI. In an RCT with 68 patients, there was
no significant difference in USSQ scores, pain at removal
or UTI rates between conventional stents and tethered
stents [122]. Fifteen percent of patients unwittingly
removed the stent prematurely without however the need
for replacement. Althaus et al. [123] reported a similar
dislodgement rate, with a clear predominance ofwomen over
men (24.4% vs. 5.3%). Consequently, if longer-term stenting is
desired, a non-tethered stent may prevent inadvertent pre-
mature removal.
In a retrospective cohort, Fröhlich et al. [124] could not
demonstrate a significant risk of UTI for tethered stents
(7.9%) in comparison to conventional stents (5.6%). Freifeld
and associates [125] on the other hand did identify more
UTI in patients with tethered stents in comparison to reg-
ular stents or non-stented patients after ureteroscopy (6.7%
vs. 3% vs. 2.1% respectively) with an OR of 7.7 (95%CI: [1.01,
58.9], p Z 0.049). In subgroup analysis, this effect was only
significant in the male population. Both studies however
are limited by the retrospective design and significant dif-
ferences in patient populations.
Loh-Doyle et al. [126] surveyed 571 patients about their
experience during stent removal. The majority of stents
(44%) was removed by office cystoscopy, 17% by cystoscopy
in the operation room and 39% by use of an extraction string
(27% by doctor, 12% by patient). Although self-removal of a
tethered stent appeared to be less painful than cystoscopic
removal, it caused considerably more delayed pain,
resulting in a higher rate of emergency department visits
(14.71% vs. 4.17%) [126].
These results were corroborated by Kim and as-
sociates [127] who nuanced that stent extraction by string
is significantly less painful only in the male subgroup. The
group also confirmed earlier findings of Barnes et al. [122],
reporting no differences in most of the USSQ domains.
Sexually active patients in the tethered stent cohort how-
ever had considerably more complaints regarding sexual
matters [127].
Patient counseling on the subsequent necessity of stent
removal after placement including potential side-effects
and education about the possibility of self-removal with a
string may aid in the adoption of this technique by both
physicians and patients.
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In an effort to prevent cystoscopic removal of a ureteral
stent, stents with a metal bead attached to the distal tip
have been developed to facilitate removal by a magnet-tip
urethral catheter [128e131].
All studies reported high success rates of 86%e97% for
removal by catheter [128e130]. Rassweiler et al. [130]
compared magnet-tip stents (Blackstar, Urotech, Ger-
many) to conventional stents in an RCT and demonstrated
an equivalent USSQ-score. The magnetic stent however
caused more pain in the groin and bladder region whereas
the regular stent caused more flank pain. Removal of the
magnet-stent was significantly faster (9.55 min vs.
21.35 min), less painful and less costly than cystoscopic
stent removal.
7.3. Biodegradable stents
In an effort to avoid any manipulation for stent
removal and to reduce the forgotten stent phenomenon
to 0, biodegradable stents are under development.
Lingeman et al. [132] reported on the first in human trial of
a biodegradable device in 87 patients. The stent was
effectively retained in 80.5% of patients for at least 48 h. In
17 patients this failed because of early stent extrusion.
Despite urethral discomfort in 68.2% during elimination, the
authors noted a high degree of patient satisfaction. In three
patients there was retention of stent fragments beyond 3
months, for which additional interventions (ESWL and/or
ureteroscopy) were needed to clear the fragments.
Uriprene, a biodegradable stent made of a variation of
biodegradable copolymers similar to those used in absorb-
able sutures, is engineered to degrade from the distal to the
proximal end to avoid ureteral obstruction by fragments.
The third generation of this stent was designed to degrade
over a shorter period of time and was evaluated in vivo in a
porcine model, demonstrating complete degradation by Day
28 in 90% while providing excellent drainage [133].
Barros et al. [134] developed a biodegradable ureteral
stentmade fromnatural origin polysaccharides. In an in vitro
study, breakdown in urine was seen after 14 to 60 days and
the stent showed good resistance to bacterial adhesion. This
new technology could also lend itself to incorporating drugs
into the biomaterial, acting as a sustained release mecha-
nism during stent degradation [135,136].
Although these stents may not become commercially
available in the next few years, human trials with this very
promising technology will demonstrate whether or not it
can hold the promise of obviating cystoscopic removal and
eliminate the forgotten stent issue.
8. Conclusion
Ureteral stents have proven their worth in the treatment
of urolithiasis. Although indications for stent placement
have decreased, the presence of a ureteral stent can
cause considerable complaints in patients. Despite cur-
rent evidence supporting several strategies in preventing
stent related symptoms or complication, widespread
adoption often lags behind. Several knowledge gaps stillexist due to the absence of adequately powered, pro-
spective RCTs. Despite the vast amount of research on
different biomaterials, stent coatings and novel designs,
the ideal stent has not yet been developed. Although
results so far are not always consistently in favour of new
developments, the future goal of reduced stent symp-
toms is not unrealistic and is being approached one step
at the time.
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